Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma

Asan Medical Center1 site in 1 country30 target enrollmentAugust 27, 2021

ConditionsPatients With Suspected or Diagnosed Central Nervous System Lymphoma

Interventions[18F]FET

Drugs[18F]FET

Overview

Phase: Not Applicable
Intervention: [18F]FET
Conditions: Patients With Suspected or Diagnosed Central Nervous System Lymphoma
Sponsor: Asan Medical Center
Enrollment: 30
Locations: 1
Primary Endpoint: Change of target to background ratio between baseline, mid-therapy and end-of treatment PET in patients with primary central nervous system lymphoma
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The overall goal of this imaging trial is to prospectively compare the usefulness of 18F-FDG PET and 18F-FET PET in evaluating treatment response and predicting prognosis in patients with central nervous system lymphoma.

Registry

clinicaltrials.gov

Start Date

August 27, 2021

End Date

March 31, 2023

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Asan Medical Center

Responsible Party

Principal Investigator

Minyoung Oh

Assistant professor

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

•In order to be eligible for participation in this trial, the subject must:
•Be ≥ 19 years of age.
•Patients diagnosed with central nervous system lymphoma by surgery/biopsy or suspected of central nervous system lymphoma by anatomical imaging examination such as MRI.
•Patients who have results or are planning to examine 18F-FDG PET in the above patients.

Exclusion Criteria

•The subject must be excluded from participating in the trial if the subject fulfil any single criteria described below:
•Pediatric and adolescent patients under 19 years of age.
•The patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) to children.
•Patients with diagnosed or suspected lymphoma lesions in organs other than the cetral nervous system.
•Based on the investigator's judgement, if the patient makes it impossible to collect complete data for a clinical trial due to personal or other reasons.
•Patients who cannot stably have PET/CT due to claustrophobia, dyskinesia, anxiety disorder, seizure, etc.
•Based on the investigator's judgement, if the patient has a serious and/or uncontrolled and/or unstable medical disease (e.g., congestive heart failure, acute myocardial infarction, severe lung disease, chronic renal disease or chronic liver disease, etc.)